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Abstract 
Urinary citrate appears to be an important factor 
in the crystallization process of calcium oxalate and cal-
cium phosphate. The urinary excretion of citrate was 
found to be significantly lower in patients with calcium 
oxalate stone disease as compared with normal subjects, 
and about 30 per cent of the calcium stone formers can 
be considered as hypocitraturic. The lowest excretion of 
citrate was recorded in urine collected during the night. 
Citrate has significant effects on supersaturation with re-
spect to both calcium oxalate and calcium phosphate, it 
also inhibits the growth of these crystals. In addition, 
citrate appears to be capable of inhibiting the aggrega-
tion of crystals composed of calcium oxalate, brushite, 
and hydroxyapatite. The heterogenous growth of calci-
um oxalate on calcium phosphate is also counteracted by 
citrate. As a consequence of the crucial role of citrate 
in these processes, stone prevention with alkaline citrate 
has become an attractive form of treatment in patients 
with recurrent stone formation. Single evening dose ad-
ministration of sodium potassium citrate resulted in an 
increased excretion of citrate, reduced levels of the cal-
cium/citrate ratio as well as supersaturation with respect 
to calcium oxalate and a decreased rate of stone forma-
tion. However, conflicting results of stone preventive 
treatment with alkaline citrate have been reported by dif-
ferent groups, and long-term follow-up of patients 
treated in a randomized way is necessary to definitely 
assess the efficacy of alkaline citrate. 
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Introduction 
Renal stone disease represents an everyday prob-
lem to urologists and nephrologists because of the high 
recurrence rate encountered in these patients. Calcium 
oxalate (CaOx) is the type of crystal most often found in 
renal calcium stones. These crystals occur either in 
monohydrate (COM) or dihydrate form or both, and fre-
quently together with calcium phosphate. A detailed un-
derstanding of the crystallization process that results in 
the formation of a renal stone is necessary for design of 
a rational recurrence preventive treatment. 
Intensive research activities in this field during 
the last 15-20 years have also definitely given us valua-
ble insights in this apparently very complicated process. 
A urine, sufficiently supersaturated with calcium oxa-
late, is certainly the most important prerequisite for 
starting the crystallization. It needs to be emphasized 
however, that a primary crystallization of calcium phos-
phate (CaP) is capable of inducing heterogenous crystal-
lization of CaOx. In this way crystallization of CaOx on 
nuclei of CaP can occur at lower supersaturation levels 
than when pure CaOx crystals are formed. The crystals 
thus formed will grow and aggregate to large crystals 
and crystal masses, that constitute the renal stone. It 
has also been demonstrated that the number and sizes of 
crystals are greater in patients with stone disease than in 
normal subjects (Robertson et al., 1971). In order to 
explain the subsequent for_mation of a renal stone it is 
also essential to consider a retention factor. The forma-
tion of a stone might thus start with a nucleation fol-
lowed by growth and aggregation of fixed or slowly 
moving crystal masses in the nephron. A number of 
urine constituents has been shown to exert effects on 
these different phases of the crystallization process, 
mainly as inhibitors of crystal growth, crystal aggrega-
tion or both. Small molecules such as pyrophosphate, 
citrate, and trace metals as well as macromolecules such 
as glycosaminoglycans, nephrocalcin, Tamm Horsfall 
mucoprotein and uropontin might be contributive in this 
respect (Robertson, 1976; Finlayson, 1977; Fleisch, 
1990; Meyer, 1990; Coe et al., 1991; Hoyer, 1992). 
During recent years, evidence has accumulated 
indicating that citrate might have a crucial role as 
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regulator of the calcium salt crystallization. Citrate can 
thereby affect supersaturation with respect to both CaOx 
and CaP by complex formation with calcium ions and in-
hibit growth of these two crystal types at least in diluted 
urine (Fleisch, 1990; Tiselius and Pomander, 1981). 
There have also been some observations of an inhibition 
of citrate on CaOx crystal aggregation. In as much as 
CaOx and CaP often are found together in calcium 
stones (Herring, 1962; Leusmann et al., 1990; Otnes, 
1983; Ohman et al., 1992), maintenance of an adequate 
urinary citrate level might, therefore, be of great impor-
tance in the treatment of patients with calcium stone 
disease. 
Attributable to the these properties of citrate, in 
addition to the reduced risk of CaOx crystallization at a 
pH above 6.5 (Tiselius, 1984; Ahlstrand et al., 1984), 
there has been a considerable interest for the use of alka-
line citrate in prevention of recurrent calcium stone 
formation. Successful results with this form of therapy 
have been reported by several authors (Butz, 1982; Pak 
et al., 1985; Preminger et al., 1988; Schwille et al., 
1987; Berg et al., 1992), but not by others (Hofbauer et 
al, 1992; Trinchieri et al., 1992). 
The aim of this review is to summarize some ex-
perimental and clinical support for the effects of citrate 
in this respect and to determine the value of citrate 
analysis in patients with calcium stone disease. 
Urinary Excretion of Citrate 
A low urinary excretion of citrate is a common 
finding in patients with calcium stone disease. The frac-
tion of patients with hypocitraturia varies between dif-
ferent reports (Butz and Knispel, 1984; Menon and 
Mahle, 1983; Nicar et al., 1983; Pak, 1991; Robertson 
eta/., 1978; Rudman eta/., 1982; Schwilleeta/., 1979; 
Welshman and McGeown, 1976; Rudman et al., 1982). 
This variation certainly reflects both different selection 
of patients and different normal levels. 
The 24 hour excretion of citrate in men and wom-
en in a large group of patients with recurrent stone dis-
ease is shown in Figure 1. During the 24 hour period 10 
per cent of the normal men excreted less than 1. 85 mmol 
and 10 per cent of the normal women less than 1. 75 
mmol. 
In our investigation, approximately 27 per cent of 
both stone forming men and women had a citrate excre-
tion below these levels. Pak (1991), who used a slightly 
lower normal citrate limit of 1. 69 mmol per 24 hours, 
found that approximately 50 per cent of the investigated 
patients were hypocitraturic. None of these observations 
gave support to a sex difference in terms of citrate ex-
cretion, which previously has been observed (Hodgkin-
son, 1962; Marangella et al., 1987). In our measure-
ments the mean (standard deviation, SD) citrate excre-
tion were in normal men and women 3.10 (1.08) and 
3.10 (1.04) mmol, respectively; and in stone-formers 
2.73 (1.70) and 2.78 (1.49) mmol. The values between 
stone formers and normal subjects differed statistically 
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Figure 1. Cumulative frequency distribution curves of 
24 hour urinary excretion of citrate in normal (N) men 
and stone-forming (SF) men (a) and normal women and 
stone-forming women (b). 
In terms of creatinine related urinary excretion, 
13 percent of the normal men had values below 125 
mmol per mol of creatinine whereas 13 per cent of the 
normal women had values below 175. Corresponding 
fractions of stone forming men and women were 33 and 
29 per cent, respectively. The mean (SD) values were 
190 (68) and 287 (181) mmol per mol of creatinine for 
normal men and women, and 191 (95) and 271 ( 129) for 
stone forming men and women. There was no signifi-
cant difference between stone formers and normal sub-
jects in this respect. If we thus define the normal range 
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Figure 2. The relationship between pH and the free cal-
cium ion concentration in a solution which contained: 
200 mmol of sodium, 80 mmol of potassium, 5 mmol of 
calcium, 3 mmol of magnesium, 0.25 mmol of oxalate, 
30 mmol of phosphate, 20 mmol of sulfate and 20 mmol 
of ammonium, per liter. 
so that it includes 90 per cent of the normal subjects, ap-
proximately 30 per cent of stone formers can be consid-
ered as hypocitraturic. This figure is in good agreement 
with results reported by others. 
Citrate forms stable and soluble complexes with 
calcium ions and is therefore efficient in modifying the 
free calcium concentration, a factor of great importance 
for the ion-activity products of both Ca Ox and CaP. 
The effect of citrate concentrations on the free calcium 
ion concentration at different pH-levels is demonstrated 
in Figure 2. The complex formation is greatest at alka-
line pH, as a result of the increased dissociation of cit-
rate. At pH 6 an increment of citrate from 1.5 to 3.0 
mmol/1 resulted in a 15 per cent reduction of the Ca++ 
concentration·. If pH simultaneously is increased to 7, 
the reduction will be 28 per cent. The most frequently 
encountered urine abnormality in calcium stone formers 
is hypercalciuria. For this reason, and in view of the 
important complex formation between calcium and cit-
rate, it might be of interest to consider the urinary 
calcium/citrate (Ca/Cit) ratio in urine (Butz, Knispel, 
1984; Hodgkinson, 1962). 
The cumulative frequency distribution curves of 
Ca/Cit-ratios (Figure 3) clearly show high values in 
stone formers. Whereas only 6 per cent of normal subj-
ects had a ratio above 3.0, as many as 35 per cent of the 
stone formers had greater values. 
The mean (SD) Ca/Cit ratios were in stone-form-
ing men and women 3.33 (3.09) and 3.16 (4. 76), respec-






20 [r] N 
0 
0 2 4 6 8 10 
Ca/Cit 
Figure 3. Cumulative frequency distribution curves of 
calcium/citrate-ratios in normal subjects and stone-
formers (1389 urine samples). 
were 1.96 (0.91) and 1.66 (0.77). The ratios were 
significantly higher in both stone-forming men (p < 
0.001) and women (p < 0.05). 
Parks and Coe (1986) found that analysis of uri-
nary calcium and citrate offered the best possibilities to 
distinguish between normal subjects and stone formers. 
Based on discriminant analysis they formulated a calci-
um-citrate index by means of which a better separation 
between the groups was obtained, than with any other 
measurement including direct measurement of the super-
saturation. The distribution pattern of calcium-citrate 
discriminant score was very similar to that obtained with 
the Ca/Cit-ratio determinations in our study. 
Diurnal Excretion Pattern of Citrate 
The citrate excretion during the day is only sub-
ject to minor variations and a comparison between the 
excretion of citrate per mo! of creatinine in 24 hour 
urine correlated very well with that recorded in a 4 hour 
urine sample collected between 0600 and 1000 hours 
(Berg, et al., 1987). This might be clinically important 
by allowing for appropriate determination of the citrate 
level even in short-term urine collections. Higher citrate 
levels were observed during daytime (Figure 4) and are 
certainly explained by the increased pH after meals. A 
low level was found during the night hours (Tiselius, 
1981a; Ahlstrand et al., 1984). 
The diurnal excretion of citrate was also studied 
by Bach et al. (1980), who observed a high citrate ex-
cretion during the day and a low excretion during the 
night. Similar to the results in Figure 4, they recorded 
peak citrate concentrations in the morning and the lowest 
levels during the late night hours. 
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Figure 4. Diurnal variation in the urinary excretion of 
citrate and calcium/citrate-ratios. The citrate concentra-
tions were calculated for a 24 hour urine volume of 1500 
ml. 
Effects of Citrate on CaOx Supersaturation 
Variations in citrate concentrations have signifi-
cant effects on the ion-activity product of CaOx 
(APcaox)- A relationship between changes in citrate 
excretion and APcaox was calculated by means of the 
EQUIL 2 program (Werness et al., 1985) in a solution 
which at pH 6.0 and in a volume of 1500 ml contained 
6.5 mmol of calcium, 4.5 mmol of magnesium, 0.3 
mmol of oxalate, 200 mmol of sodium, 70 mmol of po-
tassium, 25 mmol of phosphate, 30 mmol of sulfate, and 
35 mmol of ammonium. With this urine composition, an 
increment of 24 hour urinary citrate from 2 to 4 mmol 
resulted in a AP caox reduction from 1. 37 x 10·8 to 1. 26 
x 10·8 (mmol/1) 2 . 
Citrate was more efficient than magnesium in 
changing APcaox· The exponent for citrate was -0.22 
and that for magnesium -0.12 (Tiselius, 1991). 
Citrate affects APcaox by complex formation with 
calcium, and the citrate response is therefore more pro-
nounced in alkaline solutions. This is clearly shown in 
Figure 5. In a similar way, citrate influences the ion-
activity product of brushite, a salt that might be of im-
portance particularly for formation of stones containing 
both CaOx and CaP (Pak and Holt, 1976) (Figure 6). 
Effects of Citrate CaOx Crystal Growth Inhibition 
It has been reported by several authors that citrate 
in low concentrations is capable of inhibiting CaOx crys-
tal growth in metastably supersaturated salt solutions 
(Meyer and Smith, 1975; Ryall et al., 1981a; Tiselius et 
al., 1981). The question can be raised, however, to 
what extent does citrate contribute to the crystal growth 
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Figures 5 and 6. The effects of citrate on the ion-
activity product of CaOx (APcaox) (Figure 5) and 
brushite (AP 8 ru) (Figure 6) at pH 4, 5, 6, and 7. 
inhibition in the presence of the high concentrations of 
powerful macromolecules in urine (Tiselius et al., 1987; 
Bek-Jensen and Tiselius, 1991). To address this ques-
tion, direct determination of the crystallization was car-
ried out in whole urine samples after addition of differ-
ent amounts of citrate. As could be expected, increased 
concentrations of citrate resulted in a reduced crystalli-
zation risk, when determined by the oxalate addition re-
quired for formation of 100 crystals in the size-range of 
3.5-5 µm (Tiselius, 1985). 
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Figure 7. Effects of different concentrations of citrate 
and magnesium on the crystallization of calcium oxalate 
in a salt solution as determined from the fraction of 14C-
oxalate remaining in solution 60 minutes after super-
saturation (a) and on the ion-activity product (b). 
The effect of citrate, as well as that of magnesi-
um, was also determined in salt solutions brought to 
crystallization by supersaturation to an ion-activity pro-
duct of 4.25 x 10-8 (mol/1)2 with addition of sodium oxa-
late. As shown in Figure 7, there appeared to be a close 
relationship to the effects these compounds had on the 
supersaturation level in the sample. In an attempt to 
study this problem further, the crystal growth in samples 
containing 90 per cent of dialysed urine and CaOx seed 
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Figure 8. The ion-activity product of CaOx for the 
same precipitation of calcium oxalate in relation to the 
citrate concentration. Crystal growth was determined 30 
minutes after addition of seed crystals by measuring the 
fraction of 45Ca remaining in solution. 
concentrations at different levels of supersaturation ac-
complished by the addition of oxalate (Tiselius et al., 
1987). The growth of Ca Ox was determined by measur-
ing the amount of (45Ca) remaining in solution in the 
samples 30 minutes after addition of the seed. A re-
duced rate of calcium oxalate precipitation was recorded 
with increased citrate concentrations. In order to deter-
mine whether this effect on crystallization reflected a 
direct inhibitory action of citrate or only was the result 
of the altered supersaturation, a comparison of the 
APcaox at corresponding degrees of calcium precipita-
tion was calculated. The AP caox was calculated with the 
EQUIL 2 program. As is evident from Figure 8, the 
same CaOx precipitation was observed at increasing lev-
els of APcaox as the citrate concentration was increased. 
This indicates that citrate, even in the presence of whole 
urine concentrations of macromolecules, has the capacity 
to inhibit the growth of CaOx crystals (Tiselius, unpub-
1 ished observation). 
It is reasonable to assume that the effect of an 
increased pH on crystal growth, that has been demon-
strated in diluted urine (Tiselius, 1981b), is also valid 
for whole urine. 
Inhibition of Crystal Aggregation 
It can be assumed that the process of renal stone 
formation includes a rapid formation of large crystal 
masses. This is accomplished by aggregation of crystals 
in a way that enables their entrapment in the distal part 
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of the collecting system. In this way, the initial crystal 
formation might result in a stone nidus, that can increase 
in size to a clinically significant stone by further growth 
and deposition of crystals. It has also been shown that 
the size of crystals and crystal aggregates is greater in 
stone formers than in normal subjects (Robertson et al., 
1971). Several authors have also suggested that the inhi-
bition of crystal aggregation can be the most important 
discriminating risk factor between normal subjects and 
patients with calcium stone disease (Azoury et al., 1987; 
Coe et al., 1991; Kok et al., 1986; Springmann et al., 
1986). 
The assessment of crystal aggregation is not easy 
because of the simultaneous growth and aggregation that 
occurs in supersaturated solutions. Different methods 
can, however, give important information in this re-
spect. A detailed mathematical analysis of the change in 
crystal size distribution over time was used by Ryall et 
al. (1981), whereas the conclusions drawn by Kok et al. 
(1986, 1991) were based on kinetic analyses of the 
course of CaOx crystallization. In a nice experimental 
system, Hess et al. (1989) demonstrated the inhibitory 
properties of urinary macromolecules on COM aggrega-
tion by measuring the rate of crystal sedimentation after 
a period of slow stirring. 
We used a system similar to that of Hess et al. 
(1989), in which 0.5 ml of citrate solutions and dialysed 
urine were added to 14.5 ml of suspensions containing 
3 mg per liter of calcium oxalate monohydrate in 90 
mmol per liter sodium chloride and 10 mmol per liter 
Tris-buffer at pH 7.2. Following a 3 minute period of 
stirring, the sedimentation rate was followed by measur-
ing the absorption at 690 nm in a Perkin-Elmer Lambda 
2 spectrophotometer during the following 5 minutes. In 
this system, we were able to confirm a reduced rate of 
crystal sedimentation in the presence of urinary macro-
molecules by adding dialysed urine in different concen-
trations (Tiselius et al., unpublished observations). The 
reduced rate of crystal sedimentation is assumed to re-
flect the state of aggregation because small crystals were 
found to sediment slower than large crystals (Hess et 
al., 1989). 
In contrast to the findings by Hess et al. (1989), 
however, we observed a pronounced reduction of crystal 
sedimentation when the crystal suspension-s were pre-
incubated with citrate in concentrations corresponding to 
those in whole urine. The effects of citrate in concen-
trations between 0.8 and 3.3 mmol/1 at a pH of 7.2 is 
shown in Figure 9. The addition of citrate in the pres-
ence of dialysed urine resulted in a reduction of the sedi-
mentation rate that was higher than that observed for cit-
rate, but lower than that with only dialysed urine. Pre-
liminary results indicated that an interaction between cit-
rate and urinary macromolecules on the crystal surface 
might explain this phenomenon, but further studies in 
this respect are necessary. These results indicate that 
studies on isolated macromolecules (Felix et al., 1977; 
Koide et al., 1981), might give results different from 
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Figure 9. The sedimentation of calcium oxalate mono-
hydrate crystals at pH 7.2 in solutions containing citrate 
in the concentration range of 0.8 to 3.3 mmol/1. 
The demonstrated effect of citrate on crystal ag-
gregation gives direct support to the findings by Kok et 
al. (1986; 1991) that citrate is a very potent inhibitor of 
COM crystal aggregation. The reason for the contrast-
ing results, in comparison with those reported by Hess 
et al. ( 1989), has not been analyzed in detail, but differ-
ences in citrate concentrations, length of preincubation 
period, amount of crystals, and rate of stirring might 
have affected the result. 
The Effects of Citrate on CaP Crystallization 
A majority of calcium stones contain CaP in addi-
tion to CaOx (Herring, 1962; Otnes, 1983; Leusmann et 
al., 1990; Ohman et al., 1992) and there are certain in-
dications that patients with recurrent stone disease more 
frequently have a high content of CaP stones than those 
who only have formed one stone (Tiselius and Larsson, 
unpublished observation). The crystallization of CaP 
might be an obvio_us risk-factor in alkaline urine, a fact 
that cannot be ignored in association with prophylactic 
treatment with alkaline citrate. 
Studies on the crystal formation at different pH 
levels disclosed, that although there was a pronounced 
increment in CaP crystallization at high pH levels, the 
crystals were usually small (Tiselius, 1984). It is well 
known that citrate is an efficient inhibitor of CaP crystal 
growth (Bisaz et al., 1978; Fleisch, 1980) and several 
experiments have shown that citrate is capable of effi-
ciently inhibiting the heterogenous crystallization of 
CaOx on a hydroxyapatite surface (Berg and Tiselius, 
1989; Grases et al., 1989). 
Citrate and Calcium Oxalate Crystallization 
There is, however, only limited information avail-
able concerning the effects of citrate on CaP crystal ag-
gregation. For this reason, we measured the effects of 
citrate on the sedimentation rate of brushite and hy-
droxyapatite crystals in a way similar to that described 
above for CaOx. The results showed that citrate also ef-
ficiently reduced the sedimentation rate of these crystals 
(Tiselius et al., unpublished observation). This informa-
tion is encouraging for the further use of alkaline citrate 
in the preventive treatment of patients with recurrent 
calcium stone disease. 
Treatment of Patients with Recurrent Calcium 
Stone Disease with Alkaline Citrate 
Several authors have successfully used alkaline 
citrate preparations in prevention of recurrent calcium 
oxalate stone formation. Different preparations were 
administered, such as sodium potassium citrate, potassi-
um citrate, and magnesium citrate (Butz, 1982; Pak et 
al., 1985; Preminger et al., 1988; Schwille et al., 
1987). A 24 hour dose of 10-43 mmol given on two or 
three occasions appeared to be an efficient pharmacolog-
ical therapy with pronounced effects on stone formation. 
The rational for this therapy is the increment in urinary 
citrate that is achieved with these preparations. In view 
of the risk situation that occurs during the late night and 
morning hours, with a low citrate concentration, a low 
pH, a low urine volume and a high Ca/Cit ratio, we 
found it reasonable to administer alkaline citrate in a 
single evening dose (Berg et al., 1992). That type of 
administration would accordingly counteract crystalliza-
tion and stone formation during this particular risk peri-
od. Single dose administration might also result in a 
better patients' compliance than when the drug has to be 
administered several times a day. 
A group of 39 men and 16 women with recurrent 
calcium oxalate stone disease were treated with 5. 0 g ( 1 8 
mmol) and 3.8 g (14 mmol) of sodium potassium citrate 
respectively, as a single evening dose. Their mean (SD) 
pretreatment 24 hour urinary excretion of citrate was 1. 7 
(l.2) mmol. In these patients mean (SD) urinary citrate 
increased from 138 (98) to 253 (127) mmol per mo! of 
creatinine (p < 0.001), the Ca/Cit ratio decreased from 
5.19 (3.88) to 2.07 (1.05) (p < 0.001) and the APcaox-
index, which is an estimate of the supersaturation, was 
reduced from 2.32 (0.83) to 1.45 (0.45) (p < 0.001). 
The clinical course of the disease was favorably affected 
by alkaline citrate and the number of stones formed dur-
ing the treatment period up to 6 years [mean (SD) 3.5 
(l. 7)), was significantly lower than that recorded during 
a period of the same length following the first observa-
tion of a renal stone. The tolerance of the treatment was 
very good, certainly a result of the absence of side ef-
fects and the simplicity of drug-administration. 
As could be expected, the mean (SD) AP(CaP) in-
dex, used as an estimate of CaP supersaturation, in-
creased in morning samples from 4.1 (7.5) to 14.4 
387 
(16.9), a reflection of the increased pH. A reliable esti-
mate of this index could be obtained only in urine col-
lected between 0600 and 1000 hours. There was, how-
ever, a pronounced variation in the level of AP(CaP) 
index, and a significant increment was recorded only in 
a group of patients given an evening dose of 7.5 g. 
Further long-term follow-up studies with single 
dose administration of alkaline citrate are in progress. 
From these studies, it is particularly important to deter-
mine whether the effect on urinary pH, with this regi-
men, also is transient, as recently observed by Schwille 
et al. (1992), who gave 6 g of potassium citrate three 
times a day. Such an effect can theoretically reduce the 
therapeutic effect of alkaline citrate despite a maintained 
increment in the citrate excretion. 
A lack of stone prevention was reported by 
Trinchieri et al. (1992) who followed 19 patients treated 
with 5-10 g of potassium citrate during 2 years. They 
assumed that this might be attributable to an unaffected 
high calcium excretion. In a randomized study by 
Hofbauer et al. (1992), 25 patients treated with three 
daily doses of alkaline citrate to get a pH around 7, were 
compared with 25 patients only given metaphylactic in-
structions. The citrate was significantly higher in the 
group with alkaline citrate therapy, but there were no 
differences in the course of stone formation between the 
two groups. 
Conclusions 
Urinary citrate affects CaOx as well as CaP-crys-
tallization by reduction of the ion-activity products of 
these salts. The CaOx crystal growth is also inhibited 
by urinary citrate in a way that adds inhibitory power to 
that accomplished by urinary macromolecules. The het-
erogenous crystallization of CaOx on CaP is significant-
ly inhibited by citrate. Increments in citrate concentra-
tions result in a reduction of the aggregation of CaOx, 
brushite and hydroxyapatite crystals. Although the high 
pH associated with alkaline citrate treatment results in 
CaP crystallization, the concomitant citrate increment 
seems to be one of the most important factors in reduc-
ing the risk of this precipitation. Citrate thereby appar-
ently both maintains the crystals small and prevents the 
heterogenous growth of CaOx on CaP. The different ex-
perimental findings are supported by the successful ef-
fects of alkaline citrate on the course of calcium stone 
disease. The optimal dose and best way of administra-
tion however, has to await further long term studies. 
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Discussion with Reviewers 
W .G. Robertson: The difference in the citrate excre-
tion of stone-formers and normals in the authors' own 
study is very small and would be predicted to have a 
trivial effect on the crystallization parameters quoted. 
How do such small differences explain stone-formation 
in the authors' patients? 
Authors: It is true that the difference between stone 
formers and normal subjects in terms of mean 24 hour 
citrate excretion is relatively small. Citrate excretion 
levels below 1.0 mmol per 24 hours were, however, 
only found in stone formers and these patients might 
H.-G. Tiselius et al. 
constitute a special risk group. There is no proof that a 
low citrate excretion alone can explain why a person be-
comes a stone-former. Probably, in many patients, a 
low urinary citrate is rather a contributing factor to an 
already established risk situation, whether caused by in-
creased concentrations of oxalate or calcium, or de-
creased inhibitory activities. In addition, we know that 
a high supersaturation occurs during the night, at which 
time the pH also is low. The low pH results in a further 
reduction of citrate excretion together with a decreased 
dissociation. Such mechanisms might result in much 
reduced activity of citrate during a period when the crys-
tallization is unusually high. 
A Hesse: Is there any evidence that citrate therapy is 
effective in different ways in patients forming 
whewellite and weddelite stones, respectively? 
Authors: We have so far not studied differences in 
crystallization properties between these two crystai 
phases. All our measurements have been carried out 
with calcium oxalate monohydrate, but we are currently 
exploring the possibilities to measure at least aggrega-
tion in suspensions of calcium oxalate dihydrate. A 
comparison between stone composition (determined with 
x-ray diffraction technique) and citrate excretion indi-
cated that male patients with less than 1.5 mmol of cit-
rate excreted during 16 hours (between 0600 and 2200 
hours) had a higher content of calcium oxalate dihydrate 
in their stones. According to these preliminary results, 
16 per cent of the patients with a low citrate excretion 
had more than 70 per cent of dihydrate in their stones, 
compared with 8 per cent in patients with a higher cit-
rate excretion. 
A Hesse: Does citrate therapy favor stone passage after 
extracorporeal shock-wave (ESWL)-treatment? 
Authors: This is a very interesting and most important 
question because of the problems associated with residu-
al fragments after shock wave lithotripsy. There are a 
few observations in the literature which indicate that this 
might be the case. We have no personal experience to 
support this assumption, but we have recently started a 
randomized study to address this question. 
390 
A Hesse: High citrate concentrations in urine inhibit 
crystal aggregation or aggregation of disintegrates after 
ESWL-treatment. What kind of reaction may be respon-
sible for this observation? 
Authors: Citrate might either bind to the crystal surface 
or in any other way interact with the electrical double 
layer surrounding the crystals and/or disintegrates. 
There is also a possibility that citrate changes the physi-
cochemical properties of aggregation promoting sub-
stances in urine (e.g., Tamm Horsfall mucoprotein). 
Furthermore, can the growth inhibition reduce the risk 
of crystal bridge formation between adjacent fragments. 
B. Hess: The apparent contradiction between the au-
thors' studies and our results (Hess et al., 1989) with re-
spect to citrate as an inhibitor of calcium oxalate crystal 
aggregation, tested at almost identical conditions, might 
not really exist, if one considers that we never studied 
citrate at more than l mmolil. At this concentration, 
citrate inhibited by 7 + 3 per cent (mean + SD) in our 
system; in the authors' study, citrate at 0.83 mmol/1 
marginally promoted, whereas it slightly inhibited crys-
tal aggregation at l. 67 mmol/1. These findings seem 
fully compatible with our own results and demonstrate 
that only high physiologic concentrations of citrate in-
hibit calcium oxalate crystal aggregation under saturated 
conditions at pH 7.2. 
Authors: We agree completely with this comment. It 
is reasonable to assume that citrate concentrations above 
l mmol/1 are necessary to get measurable effects on the 
crystal aggregation in this experimental setting. For ap-
propriate evaluation of the definite role of citrate in 
terms of aggregation inhibition under physiological con-
ditions, it is certainly necessary to improve the method 
by decreasing the concentration of crystals in the suspen-
sion and to carry out the measurements at pH levels rep-
resentative for that of urine in different parts of the 
collecting system. Such work is in progress. 
